Clinical Research Progress Of Apatinib Targeted Therapy In Gastric Cancer

With the development of targeted therapy of anti-angiogenesis,effects on vascular endothelial growth factor(vascular endothelial growth factor,VEGF)and vascular endothelial growth factor receptor(vascular endothelial growth factor receptor,VEGFR)signaling pathway of antineoplastic drugs widely attention.Vascular endothelial growth factor receptor 2(vascular endothelial growth factor receptor2,VEGFR-2)inhibitors path for is a kind of high efficient anti-angiogenesis drugs,is one of the latest listed oral molecular targeted anti-tumor drugs.A series of large-scale clinical trials have confirmed Apatinib.in a variety of malignant tumors have certain objective effectiveness and survival benefit,such as stomach cancer,non-small cell lung cancer(non-small cell lung cancer,NSCLC),such as breast cancer,liver cancer,colorectal carcinoma,especially in gastric cancer.In 2014 the drug approved in China applied to clinical treatment of advanced gastric cancer.In this paper,we reviewed the latest research progress on the mechanism,safety and adverse reactions of apatinib,the clinical efficacy of different types of tumors and the evaluation criteria of curative effect.